• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Urology

UCLA Urology

UCLA Urology
  • About Us
    • Chair's Welcome
    • Awards and Recognition
    • Innovations and Technology
    • UCLA Institute of Urologic Oncology
    • Webinars
    • Contact Us
    • News and Events
    • Newsletters
    • Our History
    • Our Milestones
    • The Men's Clinic at UCLA
    • Jobs
    • Giving
  • Clinical Programs
    • Bladder Cancer
    • General Adult Urology
    • Kidney Cancer
    • Kidney Stone Center
    • Kidney Transplant Program
    • Male Urology
    • Minimally Invasive/Robotics Surgery
    • Pediatric Urology Program
    • Pelvic Medicine and Reconstruction
    • Prostate Cancer Program
    • Testicular Cancer
    • Urologic Oncology
    • Conditions Treated
  • Clinical Trials
    • Find a Doctor
    • Frequently Asked Questions (FAQ)
    • Learn More About Clinical Trials
  • For Patients
    • COVID-19 Message to Our Patients
    • Get an Expert Second Opinion
    • Telemedicine Visits Available
    • Appointment Request
    • myUCLAhealth
    • Contact Us
    • Maps and Directions
    • Clinical Updates
    • Preparing for Surgery
    • Interactive Procedure Videos
    • Patient Education
    • Patient Stories
    • Video Gallery
    • Webinars
    • Vital Signs Publications
    • UCLA Blood Donation
    • UCLA Overnight Accommodations
    • Urology Portal
  • Research
    • Bladder Cancer Research
    • Kidney Cancer Research
    • Male Urology Research
    • Pediatric Urology Research
    • Prostate Cancer Research
    • SPORE In Prostate Cancer
    • Health Services Research
    • Faculty Publications
  • Education
    • Housestaff Roster 2020-21
    • Residency
    • Fellowships
    • Medical Student Program
    • Aerial Tour: Why Choose UCLA?
  • For Healthcare Professionals
    • How to Refer a Patient
    • Physicians Updates & Clinical Updates
    • Events and CME Courses
    • eReferrals
  • Physician Directory
    • UCLA Faculty and Providers
    • Joint Appointments/Research Faculty
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Urology

Kidney Cancer

Kidney Cancer

Kidney Cancer

  • Get an Expert Second Opinion
  • Find a Doctor
  • What is Kidney Cancer
  • Symptoms & Risk Factors
  • Diagnosis
  • Types of Kidney Cancer
  • Treatment
  • Clinical Trials
  • Why Choose UCLA
  • Institute of Urologic Oncology
  • Webinars Videos & Patient Stories
  • Get an Expert Second Opinion
  • Find a Doctor
  • What is Kidney Cancer
  • Symptoms & Risk Factors
  • Diagnosis
  • Types of Kidney Cancer
  • Treatment
  • Clinical Trials
  • Why Choose UCLA
  • Institute of Urologic Oncology
  • Webinars Videos & Patient Stories
  1. Home
  2. Clinical Programs
  3. Kidney Cancer
  4. Kidney Cancer Program Achievements

Kidney Cancer Program Achievements

Share this

UCLA Institute of Urologic Oncology

30-Year Program Highlights and Accomplishments

First Decade (1989-1999)

  • Early testing of interferon and interleukin-2 as treatments for advanced kidney cancer. 
  • UCLA pioneered the understanding of the role of radical nephrectomy for patients with advanced kidney cancer and partial and "adrenal sparing" nephrectomy for small kidney tumors.  
  • UCLA awarded the first NIH-Biologic Response Modifiers Program Contract to study cytokines in kidney cancer.
  • Identification of tumor-specific Renal tumor infiltrating lymphocytes (TIL)   
  • First Gene Marking Clinical Trial in the US - Genetically engineered CD8+ and CD4+ TIL vs. PBL in RCC and Melanoma 
  • Testing of the concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A 
  • UCLA awarded an NIH, Program Project Grant in Gene Therapy as the first center to test Gene transfer into TIL   
  • UCLA issues first report on double gene transfection - RCC tumors engineered to produce both IL-2 and INFa 
  • UCLA awarded an NIH Contract -to study treatment with CD8+ TIL and IL-2   
  • UCLA performs early clinical trials using Interferon alpha-primed TIL combined with interleukin-2 and interferon alpha 
  • Development of subcutaneous interleukin-2 plus interferon alpha-2A 
  • Erythropoietin production, a potential marker for IL-2/interferon responsive tumors   
  • UCLA performs one of the first In Vivo Cancer Gene Therapies, using IL-2 Adenovirus Vector 
  • UCLA publishes a textbook on kidney cancer: Kidney Cancer; Management of 
  • UCLA pioneered the application of Health-related quality of life measurements in evaluating treatments for kidney cancer 
  • UCLA Kidney Cancer Program directors served as Co-Chairs for the Second NCI Symposium on Renal Cell Carcinoma: Recent Progress and Future Directions 
  • UCLA publishes an analysis of its first 203 consecutively treated patients using IL-2 based immunotherapy   
  • UCLA Kidney Cancer Program directors served as Chairman for the 4th International Symposium EORTC Biologic Therapy of Cancer from Basic Research to Clinical Application and the Society of Biologic Therapy 12th Annual Scientific Meeting   
  • UCLA presents research that human dendritic cells can activate tumor infiltrating lymphocytes against autologous tumor: 
  • UCLA publishes its experience with metastatic RCCa with concurrent IVC invasion showing long term survival following combination therapy using radical nephrectomy, vena cava thrombectomy, and postoperative immunotherapy 
  • UCLA directs a multicenter randomized phase II/III trial of CD8+ TIL in combination with recombinant IL-2   
  • Construction of the first Kidney Cancer Microarray (340 Patients) 
  • Completion of the Phase 1 UCLA Kidney Cancer Database (1,498 patients; 263 variables/patient) 
  • UCLA publishes its experience expanding the indications for surgery and adjuvant IL-2 based immunotherapy   
  • First testing of Intratumoral IL-2 for renal cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex 
  • UCLA develops and publishes its UCLA Integrated Staging System (UISS) 
  • UCLA performs A Phase I/II pilot study of KW-2189.

Second Decade (2000-2009)

  • The Henry Alvin and Carrie L. Meinhardt Chair in Kidney Cancer Research is established   
  • An analysis of 124 patients with of metastatic RCC treated with high-dose bolus interleukin-2 in a non-intensive care unit is published   
  • Development of aG250 targeted and T-cell mediated anti-tumor activity against RCCa using a chimeric fusion protein consisting of G250 and granulocyte-monocyte colony stimulating factor 
  • The UCLA Integrated Staging System (UISS), for patients with renal cell carcinoma is validated 
  • Arie Belldegrun, MD, FACS serves as Guest Editor for New issues in RCC, Seminars in Urologic Oncology, and Renal and Adrenal Carcinoma, Atlas in GU Oncology   
  • UCLA performs its first Laparoscopic Radical nephrectomy 
  • Arie Belldegrun, MD, FACS awarded the Roy and Carol Doumani Chair in Urologic Oncology 
  • UCLA develops a mathematical model to predict individual survival for patients with renal cell carcinoma 
  • UCLA an early leader in cryoablation and minimally invasive ablative approaches for renal tumors   
  • UCLA an early site to test the usefulness of F-18 deoxy-glucose whole body positron emission tomography (PET) for staging of advanced renal cell cancer 
  • UCLA Kidney Cancer Program directors served as Chair of the 2nd International Kidney Cancer Symposium, Chair, Novel Approaches to Advanced Disease and participated in the International Conference on Staging Renal Cell Carcinoma, Lyon, France, October 2002   
  • UCLA develops the AUA Patient Education Website: Kidney Tumors 
  • UCLA first to report that Carbonic Anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma and a marker of IL-2 response. 
  • Arie Belldegrun, MD, FACS, gives the Plenary Session Lecture on Kidney Cancer at the American Urological Association Annual Meeting, May 2003, Renal Cell Carcinoma, San Francisco, CA.
  • A novel kidney cancer immunotherapy developed in the UCLA Belldegrun Research Laboratory that is based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene chosen to be further developed by the NIH RAID program 
  • UCLA publishes data on the role of lymph node dissection, and the impact of lymph nodes on survival, and benefits of immunotherapy   
  • Development of LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen 
  • UCLA develops a scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials 
  • UCLA performs a pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma 
  • UCLA Kidney Cancer Program directors serve as Editors, Renal and Adrenal Tumors, Oxford University Press, Oxford, England and Cancer Treatment and Research Book Series: Kidney Cancer, Kluwer Academic Publishers 
  • UCLA Kidney Cancer Program launches hands-on educational courses for urologists in cryosurgical ablation of renal tumors 
  • UCLA Kidney Cancer Program Director appointed to the American Urological Association's Kidney Cancer Guideline Committee (2007) 
  • 15- Year Survival Data of the UCLA Kidney Cancer Program presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (Chicago - May 2007)
  • Arie Belldegrun, MD, FACS, delivers the keynote Andrew C. Novick Memorial Lecture at the Ninth International Kidney Cancer Symposium in Chicago.
  • Fairooz Kabbinavar, MD, presents promising Preliminary Results from a Phase I trial of a novel combination of targeted therapies in patients with advanced kidney cancer at the Ninth International Kidney Cancer Symposium in Chicago, as well as data on the efficacy and safety of a developmental drug for kidney cancer at the annual meeting of the European Society of Medical Oncology.
  • Allan Pantuck, MD, is awarded a grant to study the immunological effects of focal high intensity frequency ultrasound alone and in combination with cancer vaccines.
  • Brian Shuch, MD initiated several projects involving sarcomatoid transformation in renal cell carcinoma. These studies questioned the role of upfront cytoreductive nephrectomy in this population and described a pattern of subclonal spread.
  • UCLA publishes several articles including the use of DNA alterations in the CAIX gene to predict prognosis and personalized selection of patients for Interleukin-2 therapy, the investigation of mutations in chromosome 9 to distinguish benign from aggressive small kidney tumors, and development of molecular tools to identify patients’ risk of dying from kidney cancer.

Third Decade (2010-2019)

  • Drs. Mark Litwin and Christopher Saigal work with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiated the Urologic Diseases in America (UDA) project in 2001 with the goal of quantifying the immense demographic burden of urological diseases on the American public. They specifically outline the current status of kidney cancer with surgery and systemic therapy treatments.
  • Christopher Saigal, MD led efforts to determine practice patterns with renal mass biopsy in the United States
  • Alexandra Drakaki, MD presented her work the UCLA CAIX vaccine therapy trial in a plenary session at the Kidney Cancer 
  • Dr. Mark Litwin helped describe patterns of diffusion of surgical innovation for kidney cancer which depends more on their surgeon's practice style than on the characteristics of the patient
  • Drs. Saigal and Shuch’s work with the Urologic Diseases of America project highlight that all types of kidney cancer treatments can pose adverse health outcomes when compared to active surveillance. 
  • Drs. Saigal and Shuch demonstrate that the perceived improvement in outcome with partial nephrectomy over radical nephrectomy is strongly influenced by selection bias.
  • Genetic counseling referral guidelines for “early onset of hereditary kidney cancer was defined in by Dr. Brian Shuch in 2014 in the Journal of Clinical Oncology.
  • Dr. Brian Shuch leads first study describing the use of multigene panel testing for hereditary kidney cancer syndromes in Cancer in 2017.
  • Dr. Shuch leads several clinical efforts describing the outcome of sarcomatoid transformed kidney cancer. He later describes the genomics of sarcomatoid kidney cancer in 2016 in a landmark paper in the Proceedings of the National Academy of Sciences
  • Dr. Arie Belldegrun leads an international effort to evaluate adjuvant therapy for high risk kidney cancer using a monoclonal antibody to CAIX.
  • Dr. Karim Chamie reports that increased body mass index improves outcome in patients with advanced kidney cancer
  • In 2017, Dr. Allan Pantuck publishes landmark paper on adjuvant systemic therapy with Sunitnib. Dr. Pantuck also presented before the Oncology Drug Advisory Committee and the FDA leading to the approval of the first approved adjuvant drug for kidney cancer.
  • Dr. Brian Shuch receives K08 grant from the National Institutes of Health to study genomic heterogeneity in small renal mass. 
  • Drs. Allan Pantuck and Brian Shuch named to the Society of Urologic Oncology Clinical Trials Committee for Renal Cancer
  • Dr. Brian Shuch named SWOG Co-Chair of the Renal Committee.
  • Dr. Chamie led pivotal pre-clinical work that has led to the development of the first-ever chemo-ablative agent for low-grade upper tract urothelial carcinoma of the kidney
  • Dr. Chamie’s research lab is expanding the role of locally administered immunotherapeutic agents for the treatment of high-grade upper tract urothelial carcinoma of the kidney in order to limit the need for kidney removal.
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest